证据表明,在狗的认知功能障碍中,阿尔茨海默病的新兴转录组媒介存在
Shelby C Osburn1,2, Darby S Easterday1, Cali M McEntee1,2
1Department of Health & Exercise Science, Colorado State University, Fort Collins, Colorado, USA.
Brain pathology (Zurich, Switzerland)
|December 22, 2025
概括
伴侣犬表现出大脑衰老和认知衰退,类似于患有阿尔茨海默氏症 (AD) 的人类. 这项研究发现了共享的转录基因变化,包括细胞外囊中的可转移元素和microRNA,这表明狗是AD研究的有价值模型.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 比较医学是一种比较医学.
背景情况:
- 伴侣狗随着年龄的增长表现出认知能力的下降,反映了人类阿尔茨海默氏症 (AD) 的各个方面.
- 虽然犬类认知功能障碍 (CCD) 和AD之间存在病理上的相似之处,但转录基因相似之处仍未得到充分探索.
- 细胞外囊 (EVs) 中的可转移元素 (TE) 和微RNA (miRNA) 与人类大脑衰老和AD有关.
研究的目的:
- 调查犬类认知功能障碍 (CCD) 和人类阿尔茨海默病 (AD) 之间的转录学相似之处.
- 为了确定TE和miRNA的变化,可能由EVs介导,是否存在于狗大脑衰老和CCD.
主要方法:
- RNA测序 (RNA-seq) 在前额叶皮层组织和来自年轻,年长和CCD受影响的狗的血EV上进行.
- 全转录组分析的重点是确定与神经元健康,TE和miRNAs相关的变化.
主要成果:
- 在CCD犬的全球转录组变化表明神经元健康降低.
- 在CCD狗的大脑和血EV中,TE转录的升高.
- 在血EV中检测到与大脑和疾病相关的miRNA,其中一些与认知功能指标相关.
结论:
- 狗类认知功能障碍的转录组变化与人类阿尔茨海默病有相似之处.
- 在EV中高的可转移元素和特定的microRNA可能代表大脑衰老和神经退行过程中的保存机制.
- 伴侣狗是研究大脑衰老和AD的分子基础的相关模型.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.3K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.9K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
